BPC-157 and Hepatic Ischemia: Liver Blood Flow Research

BPC-157 and Liver Protection

30 min

In the Pringle maneuver model, BPC-157 activated a portocaval shunt pathway and normalized portal hypertension within minutes of administration during hepatic ischemia in rats.

Kolovrat et al., World J Hepatol, 2020

Kolovrat et al., World J Hepatol, 2020

View as image

When surgeons need to operate on the liver, they sometimes clamp the portal triad, a procedure called the Pringle maneuver, to control bleeding. This deliberate interruption of blood flow creates ischemia, and restoring flow afterward triggers reperfusion injury, a paradoxical second wave of damage from oxidative stress and inflammation. In 2020, a Croatian research team demonstrated that BPC-157, a 15-amino-acid gastric pentadecapeptide, resolved both the ischemic and reperfusion phases of the Pringle maneuver in rats by rapidly activating an alternative blood flow pathway.^[1] That study represents the most detailed investigation of BPC-157's hepatic vascular effects to date, but it is one piece of a larger body of liver protection research spanning three decades.

The Pringle Maneuver Model

The Pringle maneuver is a standard surgical technique used during liver operations to temporarily stop hepatic blood flow by clamping the hepatoduodenal ligament. It controls hemorrhage but creates two distinct injury phases: ischemia during clamping and reperfusion injury when flow is restored. Both phases damage hepatocytes, trigger inflammation, and can lead to multi-organ complications.

Kolovrat et al. (2020) used this surgical model to test BPC-157's hepatoprotective capacity in rats.^[1] The portal triad was clamped for 30 minutes, followed by either 15-minute or 24-hour reperfusion periods. BPC-157 was administered at 10 micrograms or 10 nanograms per kilogram as a single dose at various time points: before ischemia, during ischemia, or at different stages of reperfusion.

What happened during ischemia

In untreated control rats, portal triad obstruction produced severe hemodynamic disturbances: portal hypertension, aortal hypotension, tachycardia, and ECG changes including increased P wave amplitude and an S1Q3T3 QRS pattern (a marker of right heart strain). Thrombosis formed in portal vein tributaries, the inferior caval vein, and the hepatic artery. Liver histology showed dilated central veins and terminal portal venules. Lung tissue showed severe capillary congestion. The intestine exhibited capillary congestion, submucosal edema, and loss of villous architecture.

BPC-157-treated rats showed a fundamentally different vascular response. The peptide rapidly activated a portocaval shunt pathway: portal vein to superior mesenteric vein to inferior mesenteric vein to rectal veins to left ileal vein to inferior caval vein. This alternative pathway immediately affected hemodynamics, markedly attenuating portal hypertension and aortal hypotension during the clamping period. Thrombosis was counteracted across all affected vessels.

What happened during reperfusion

Reperfusion in control rats worsened rather than resolved the damage. Portal and caval hypertension persisted, aortal hypotension continued, refractory ascites formed, and the multi-organ injury progressed. In BPC-157-treated rats, reperfusion disturbances were "completely abrogated" rather than merely attenuated, including elimination of ascites formation and normalization of hemodynamic parameters.^[1]

This study demonstrated that BPC-157's hepatic protection operates through a vascular mechanism rather than direct hepatocyte protection alone. The peptide did not simply reduce liver cell death; it rerouted blood flow around the obstruction.

The Vascular Recruitment Mechanism

The Pringle maneuver study did not emerge in isolation. BPC-157's ability to recruit collateral blood vessels had been documented in multiple vascular obstruction models before the liver-specific work.

Seiwerth et al. (2014) reviewed BPC-157's effects on blood vessels across injury types, concluding that the peptide functions as an angiomodulatory agent acting through NO, VEGF, and FAK pathways. After vessel obstruction, BPC-157 activated blood vessels "running towards bypassing defect," establishing functional collateral circulation.^[2]

Sikiric et al. (2018) described this as the third component of BPC-157's cytoprotective mechanism: beyond cell protection and endothelium protection, the peptide actively controls blood vessel function depending on the type of injury. After a perforating injury, BPC-157 directs vessels toward the defect. After an obstruction, it activates bypass routes.^[3] This distinction matters for hepatic ischemia because liver damage from blood flow interruption is fundamentally an obstruction problem.

Vukojevic et al. (2018) demonstrated this mechanism in inferior caval vein ligation, a model that recapitulates Virchow's triad of vessel injury, stasis, and thrombosis. BPC-157 counteracted direct vein injury, thrombosis, thrombocytopenia, and prolonged bleeding while rapidly presenting collateral pathways and redistributing trapped blood volume. The peptide raised plasma NO values while normalizing oxidative stress markers (MDA), and altered expression of EGR, NOS, SRF, VEGFR, and KRAS genes across multiple veins.^[4] For BPC-157's vascular effects beyond the liver, including cardiac applications, the same collateral recruitment pattern appears across organ systems.

Ischemia-Reperfusion Beyond the Liver Itself

Hepatic ischemia does not damage only the liver. When blood flow to the liver is interrupted and then restored, inflammatory mediators and reactive oxygen species enter systemic circulation, injuring distant organs.

Demirtas et al. (2025) examined this phenomenon from the opposite direction: lower-extremity ischemia-reperfusion injury causing distant damage to the liver, kidneys, and lungs.^[5] After 45 minutes of lower-extremity ischemia followed by 2 hours of reperfusion in rats, BPC-157 administered at the start of the procedure significantly reduced liver pathology. Sinusoidal dilation, necrotic cells, and mononuclear cell infiltration were all significantly lower in treated animals compared to ischemia-reperfusion controls. Total antioxidant status (TAS) increased while total oxidant status (TOS) and oxidative stress index (OSI) improved across liver, kidney, and lung tissues.

This study extends BPC-157's hepatoprotective evidence from direct liver ischemia to systemic ischemia-reperfusion damage reaching the liver secondarily. The mechanism again involved antioxidant activity and anti-inflammatory effects rather than organ-specific targeting.

Duzel et al. (2017) had previously demonstrated BPC-157's ischemia-reperfusion effects in a colitis model, where the peptide restored blood supply to ischemically injured tissue by rapidly activating collateral vessels. The researchers concluded that "BPC 157 is a fundamental treatment that quickly restores blood supply to the ischemically injured area and rapidly activates collaterals" through the NO system.^[6]

Portal Hypertension and Chronic Liver Injury

Acute ischemia is not the only blood flow problem in the liver. Chronic liver disease from alcohol, toxins, or bile duct obstruction can cause sustained portal hypertension, the persistent elevation of blood pressure in the portal venous system that drives many complications of cirrhosis.

Alcohol-induced portal hypertension

Prkacin et al. (2001) tested BPC-157 in rats given 7.28 g/kg/day of alcohol in drinking water for 3 months.^[7] Portal hypertension was measured directly in the portal vein. Control rats developed significantly elevated portal pressure, increased hepatocyte size and nuclear area, advanced steatosis, and increased liver weight.

BPC-157 (10 micrograms or 10 nanograms per kilogram, given intraperitoneally or intragastrically) produced both prophylactic and therapeutic effects. When given for the full 3 months alongside alcohol, it prevented portal hypertension. When started only in the third month, it reversed already-established portal hypertension to values seen in healthy rats. Portal pressure, hepatocyte circumference and area, and liver weight all normalized. Propranolol showed similar efficacy, while ranitidine attenuated only steatosis. For deeper coverage of BPC-157 and alcohol-related liver damage, the evidence extends beyond portal pressure to hepatocyte morphology and fat accumulation.

Bile duct ligation

Sever et al. (2019) tested BPC-157 in rats with bile duct ligation, a model that produces progressive liver fibrosis and portal hypertension.^[8] Over 8 weeks of follow-up, BPC-157 given in drinking water (0.16 micrograms/ml, approximately 12 ml per rat per day) markedly reduced jaundice, ascites, liver nodularity, and steatosis. Serum markers (AST, ALT, GGT, ALP, bilirubin) improved. Histologically, the peptide counteracted piecemeal necrosis, focal lytic necrosis, apoptosis, and disturbed cell proliferation.

At the molecular level, BPC-157 normalized tissue MDA and NO values, altered NOS2 and NOS3 expression in liver tissue, and decreased inflammatory cytokines (IL-6, TNF-alpha, IL-1-beta). Portal hypertension was either prevented entirely or rapidly reduced depending on when BPC-157 treatment began.

Radiation-Induced Liver Injury

Hepatic ischemia from vascular obstruction is one mechanism of liver damage. Radiation-induced liver disease (RILD) represents another, where therapeutic radiation for cancer damages hepatic vasculature and hepatocytes through oxidative stress.

Huang et al. (2022) irradiated mice with a single 12 Gy dose to induce acute liver injury and administered oral BPC-157.^[9] The peptide reduced plasma AST and ALT levels and inhibited hydropic degeneration of the liver. BPC-157 decreased radiation-induced cell apoptosis, increased PCNA expression (a marker of cell proliferation), promoted KLF4 expression, decreased hepatic lipid accumulation, and reduced HIF-2-alpha expression both in vivo and in vitro.

The mechanistic insight was specific: siRNA knockdown of KLF4 abolished BPC-157's protective effects on radiation-induced apoptosis and lipid accumulation, establishing KLF4 upregulation as a necessary mediator of the peptide's radioprotective action in liver cells. This is one of the few BPC-157 studies to identify a single gene whose knockdown eliminates the therapeutic effect.

The Original Hepatoprotective Study

The foundation for all subsequent hepatic ischemia work was laid in 1993. Sikiric et al. tested BPC-157 across three liver injury models in rats: 24-hour bile duct plus hepatic artery ligation, 48-hour restraint stress, and carbon tetrachloride (CCl4) administration.^[10]

BPC-157, given either intragastrically or intraperitoneally, significantly prevented liver necrosis and fatty changes in all three models. Laboratory values for bilirubin, SGOT, and SGPT correlated with histological findings. Critically, BPC-157 outperformed three reference drugs: bromocriptine, amantadine, and somatostatin, which had either minimal or no protective effects in the same models.

This study is worth noting for two reasons. First, it established BPC-157's hepatoprotective activity across mechanistically distinct injury types (surgical, stress-related, and chemical). Second, oral administration was effective, an unusual property for peptides. The bile duct plus hepatic artery ligation model directly involves hepatic ischemia, making this the first demonstration of BPC-157's capacity to protect against liver blood flow interruption.

What These Studies Do Not Show

Every study described above was conducted in rats or mice. No human clinical trial has tested BPC-157 for hepatic ischemia, portal hypertension, ischemia-reperfusion injury, or any form of liver blood flow disruption. The broader BPC-157 evidence landscape contains approximately 30 total human subjects across all indications, none of them liver patients.

The vascular recruitment mechanism, while consistently demonstrated across models, has been studied almost exclusively by the Sikiric group at the University of Zagreb. Independent replication of the Pringle maneuver results by other laboratories has not been published. The 2025 Demirtas study from a Turkish group represents one of the few non-Zagreb contributions to BPC-157's ischemia-reperfusion evidence base.

Dose translation from rats to humans is not straightforward. The effective doses in rat studies (10 micrograms to 10 nanograms per kilogram) cannot be linearly scaled to human dosing. Route of administration matters as well: the Pringle maneuver study used both intraperitoneal injection and direct bath application to the surgical site, neither of which has a direct clinical equivalent that has been safety-tested. The FDA's regulatory position on BPC-157 reflects these unknowns.

The consistency of BPC-157's hepatoprotective effects across acute ischemia, chronic alcohol exposure, bile duct obstruction, radiation injury, and distant ischemia-reperfusion damage is the strongest argument for further investigation. Whether that consistency in animal models translates to any clinical benefit remains entirely untested.

The Bottom Line

BPC-157 demonstrates consistent hepatoprotective effects across multiple rat and mouse models of liver blood flow disruption, including the Pringle maneuver, chronic alcohol-induced portal hypertension, bile duct ligation, and radiation-induced liver injury. The primary mechanism involves rapid collateral vessel recruitment to bypass obstructed blood flow, mediated through NO, VEGF, and related pathways. All evidence is preclinical; no human trial has tested BPC-157 for any hepatic ischemia indication.

Frequently Asked Questions

What is the Pringle maneuver and why does it cause liver damage?

The Pringle maneuver is a surgical technique that temporarily clamps the portal triad (hepatic artery, portal vein, and bile duct) to control bleeding during liver surgery. The 30-minute blood flow interruption creates ischemia, and restoring flow triggers reperfusion injury from oxidative stress and inflammation. In a 2020 rat study, BPC-157 activated an alternative blood flow pathway that bypassed the clamp, normalizing hemodynamics during both phases.

Does BPC-157 protect the liver from ischemia?

In rat models, BPC-157 has consistently reduced liver damage from ischemia-reperfusion injury. The most detailed study (Kolovrat et al., 2020) showed the peptide activated a portocaval shunt pathway during hepatic ischemia, counteracted thrombosis, and normalized portal hypertension. A 2025 study showed BPC-157 also protected the liver from distant ischemia-reperfusion injury originating in the lower extremities. No human trial has tested these effects.

Can BPC-157 reverse portal hypertension?

In rat studies, BPC-157 both prevented and reversed portal hypertension. Prkacin et al. (2001) showed that BPC-157 normalized portal vein pressure in rats with chronic alcohol-induced portal hypertension, even when treatment started after 2 months of damage. Sever et al. (2019) showed similar results in a bile duct ligation model. These are animal studies; no human clinical data exists for BPC-157 and portal hypertension.

How does BPC-157 protect liver blood vessels?

BPC-157 appears to work through three vascular mechanisms: activating collateral blood vessel pathways to bypass obstructions, counteracting thrombosis in affected vessels, and normalizing nitric oxide (NO) signaling. A 2018 review classified BPC-157 as a cytoprotective agent that controls blood vessel function depending on injury type, directing new vessel growth toward defects after perforating injuries and activating bypass routes after obstructions.

Has BPC-157 been tested in humans for liver disease?

No. Every study on BPC-157 and hepatic ischemia, portal hypertension, or liver blood flow has been conducted in rats or mice. The total published human data for BPC-157 across all conditions involves approximately 30 subjects, none of them liver patients. The FDA has classified BPC-157 as Category 2, indicating potential safety risks for compounding use.

Does BPC-157 work against radiation liver damage?

In mice, oral BPC-157 reduced radiation-induced liver injury by decreasing liver enzyme levels (AST, ALT), inhibiting hepatocyte apoptosis, and reducing hepatic lipid accumulation. Huang et al. (2022) identified KLF4 upregulation as the necessary mechanism: when KLF4 was knocked down, BPC-157's protective effects were abolished. This finding has not been replicated or tested in humans.